Compare Novartis AG (NVS) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard High Dividend Yield ETF — how do they compare? Novartis AG trades at $142.98 (market cap $268.57B), while Vanguard High Dividend Yield ETF trades at $158.56 (market cap $100.80B). The key difference: Novartis AG is far larger — about 2.7× Vanguard High Dividend Yield ETF's market cap, and Novartis AG pays a 3.31% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| NVS | VYM | |
|---|---|---|
Market Cap | $268.57B | $100.80B |
Volume | 1,532,573 | 908,176 |
Sector | Health | — |
52-Week High | $168.62 | $167.03 |
52-Week Low | $121.80 | $137.47 |
Typical Hold Time | 82 Days | 138 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
VYM trades at $157.45, down 0.58% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with support at $157 and resistance at $158. Recent news highlights VYM's consistent dividend yield of 2.42% but notes performance lag versus peers like SCHD and IDV, which have outperformed year-to-date.
VYM faces competition from higher-yielding alternatives and exhibits vulnerability to dividend cuts in its holdings. The ETF's broad diversification provides stability, but investors may seek better returns elsewhere. Key risks include sector concentration and interest rate sensitivity affecting dividend appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
